Thoracic Surgeon at IRCCS National Cancer Institute of Rome. Research Fellow at McGill University, Montréal.
Roma, Lazio
Joined January 2012
- Tweets689
- Following671
- Followers357
- Likes6.1K
Filippo Gallina retweeted
📌 LungÕ 2026 – Virtual Global Congress on Lung Oncology | Opening Sessions
LungÕ 2026 – Virtual Global Congress on Lung Oncology brings together international experts to explore the latest developments in lung cancer prevention, diagnosis, and treatment, with a focus on translating scientific advances into practical, evidence-based approaches to patient care.
The opening remarks by Estelamari Rodriguez (@Latinamd) set the stage for a programme addressing some of the most important questions shaping lung oncology in 2026.
The scientific discussions explored the evolving treatment landscape of non-small cell lung cancer (NSCLC), highlighting the importance of personalised, multidisciplinary decision-making.
Dobbie Pei-Hsing Chen examined why the newest treatment is not always the right treatment, emphasising individualised care for patients with metastatic NSCLC.
Myung-Ju Ahn addressed the changing first-line treatment decisions in EGFR-mutant NSCLC, comparing osimertinib, FLAURA2, and MARIPOSA, while Yi-Long Wu explored treatment strategies beyond the immunotherapy reflex through ADAURA, ALINA, and LAURA in driver-positive NSCLC.
Another important focus was the changing role of surgery and treatment personalisation across different patient populations. Tetsuya Mitsudomi (@t_mitsudomi) discussed decision-making in resectable NSCLC, examining when surgery is appropriate and when systemic treatment should take priority.
Adeline Gonzales highlighted the importance of looking beyond chronological age and ECOG performance status when individualising lung cancer treatment for older adults. Meanwhile, Filippo Gallina (@filippog92) explored the evolving role of surgery within multimodal lung cancer treatment, particularly in the context of perioperative systemic therapies.
The discussions also addressed the importance of early detection and global access to lung cancer care. Abhishek Shankar (@ShankarAbhishek) examined the challenges and opportunities of implementing lung cancer screening programmes in low- and middle-income countries (LMICs), highlighting an important dimension of improving early detection worldwide.
Together, these opening sessions reflect the rapidly evolving landscape of lung oncology, from screening and early detection to biomarker-driven treatment decisions, multidisciplinary care, and the integration of surgery with systemic therapies.
The discussions emphasise the importance of bringing scientific progress into everyday clinical practice while ensuring that treatment decisions remain tailored to individual patients.
🔴 Live sessions available here: teapaw.org/i/broadcasts/2vylnealj…
🔗 Explore and learn more about LungÕ 2026 – Virtual Global Congress on Lung Oncology: oncodaily.com/lungo-2026-vir…
#LungÕ2026
Filippo Gallina retweeted
Non-randomized phase II study of neoadjuvant ivonescimab in pts with resectable NSCLC @NatureMedicine. Ivonescimab alone (n=10): MPR 60%, pCR 30%. Ivo + chemo (n=67) MPR 70%, pCR 51% (61% in squamous). Only 1 treatment related surgery delay.
nature.com/articles/s41591-0…
Filippo Gallina retweeted
Wow! If such high pCR rates are replicated in larger trials, we next need to identify reliable algorithms to predict pCR and determine whether there are patients in whom we can omit surgery.
🔥Perioperative ivonescimab ± chemo in resectable NSCLC
🆙 @NatureMedicine
🎯Primary endpoint met
🎯Cohort 2 (ivonescimab + chemo): MPR 70.1% (47/67), pCR 50.7% (34/67), RVT≤5% 97.9% (46/47)
🎯Cohort 1 (monotherapy) MPR 60.0% (6/10), pCR 30.0% (3/10), RVT≤5% 83.3% (5/6)
🎯All patients who underwent surgery achieved R0
🎯Grade ≥3 TRAEs 30.4%; no grade ≥3 hemorrhage or treatment-related death
🎙Dr. Xiaoliang Zhao
#LCSM @OncoAlert @Larvol
nature.com/articles/s41591-0…
Filippo Gallina retweeted
🫁 Lobectomy, segmentectomy or wedge resection in stage I NSCLC?
Join ESTS as three experts debate:
▪️ Hisashi Saji: Segmentectomy for tumours <2cm (JCOG0802)
▪️ Nasser Altorki: Is wedge resection equally good?
▪️ Eric Lim: Lobectomy as the gold standard
📅 9 Nov | 6 PM CET
ALT ESTS webinar technical session titled "Lobectomy, segmentectomy or wedge in Stage I NSCLC — how to interpret the evidence," chaired by an ESTS surgeon from Austria, featuring three international thoracic surgeons; save the date 9 November 2026, 6:00 PM CET.
Filippo Gallina retweeted
When we presented data from all the neoadjuvant/periop IO studies people were understandably concerned about what happened to those who didn’t get operated. People were also confused by the stage overlap between PACIFIC and the surgical trials. So the goal of MDT-BRIDGE was to better understand these gaps and evaluate whether an early MDT reassessment after 2 cycles could allow most patients to achieve definitive locoregional control, which they did in 95% of cases. MDT reassessment also enabled very high R0 rates. Complication profile for the CRT group seemed reasonable as well which was another gap in knowledge. The goal wasn’t AT ALL to compare the survival outcomes between the two forms of locoregional therapy. Our intent was to bring data to areas of uncertainty after multiple phase 3 trials. We also wished to understand why MDTs might interpret resectability differently and this work is still ongoing.
The data are also not meant to be used to justify a trial. Before such an RCT could be done, I think the Rad Onc community would have to prove that neoadj chemoIO followed by CRT is superior or at least equivalent to PACIFIC. Once this is done, we can talk about the RCT… still much work to be done.
Filippo Gallina retweeted
Meet our LungÕ 2026 speaker: Filippo Gallina!
(@filippog92)
We’re delighted to welcome Dr. Filippo Gallina, Thoracic Surgeon at IRCCS Regina Elena National Cancer Institute, Rome, Italy, to #LungÕ2026 – Virtual Global Congress on Lung Oncology.
Join us for a global exchange of ideas on advancing lung cancer care.
📅 November 5, 2026
🌐 Virtual congress: oncodaily.com/lungo-2026-vir…
Filippo Gallina retweeted
Dopo anni di aumento vertiginoso di diseguaglianze, povertà, emarginazione, stupirsi perché qualcuno spacca qualche vetrina è un po’ da dilettanti. Mi appello al più grande dei milanesi: “I poveri, ci vuol poco a farli apparir birboni”. (Alessandro Manzoni, I Promessi sposi)
Multidisciplinary Management of Stage III Non-Small Cell Lung Cancer in the Immunotherapy Era: An Italian Delphi Consensus from AIOM, SICT, SIAPEC, and AIRO - JTO Clinical and Research Reports jtocrr.org/article/S2666-364…
@JTOonline @AIOMtweet
Filippo Gallina retweeted
🆕article in press: Thymic radiation is associated with worse outcomes in patients with NSCLC @Simon_Bernatz @nbirkbak @Dr_RayMak @HugoAerts
doi.org/10.1016/j.annonc.202…
Filippo Gallina retweeted
🆕article in press: Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer @DrMarkAwad @JordiRemon
doi.org/10.1016/j.annonc.202…
Filippo Gallina retweeted
Amazing results! Oddly reminiscent of your first NEJM @FordePatrick for Nivo monotherapy!
🆙#WCLC26 #LCSM Oral Session
🔥NAUTIKA1: Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC
🎙️ @ChaftJamie
🔢OA04.04
🎯MPR 42%, pCR 16% (n=19)
🎯Radiographic ORR 55%
🎯No Treatment Discontinuations Due to AEs
☑️NCT04302025
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC @KRASKickers
Filippo Gallina retweeted
🆕 Article in press: Five-year outcomes of perioperative pembrolizumab for early-stage non–small-cell lung cancer from the randomized KEYNOTE-671 study
@HwakeleeMD @DoctorJSpicer @marinagarassino
🔗doi.org/10.1016/j.annonc.202…
Filippo Gallina retweeted
Next step lung cancer? Adjuvant personalized vaccine improves outcomes in resected melanoma. Trials either fully accrued or ongoing in lung! #lcsm merck.com/news/merck-and-mod…
Filippo Gallina retweeted
Outstanding manuscript now in Nature from Drs. Tina Cascone, @marianoprovenci & colleagues. Setting the bar for translational correlates in phase 3 cancer trials.
Use of liquid biomarkers of systemic therapy is coming soon in early stage cancer! #lcsm nature.com/articles/s41586-0…
Filippo Gallina retweeted
A fascinating look at molecular response in resectable NSCLC from CM77T. Perioperative nivolumab increased presurgical ctDNA clearance (66% vs 38%), while all 13 patients who converted from MRD− to MRD+ during adjuvant therapy ultimately recurred. @Nature
Nature publication today from Dr. Tina Cascone et al with tremendous detail on biomarkers from CheckMate 77T predicting benefit from perioperative nivolumab in patients with resectable NSCLC. Amazing amount of detailed data in this @Nature paper.
nature.com/articles/s41586-0…
Filippo Gallina retweeted
‼️ A tumour isn’t necessarily the same all the way through.
Different populations of cancer cells can exist within it and evolve over time, including under the pressure of treatment.
A new Nature Cancer review looks at how understanding and tracking that evolution could lead to better ways to diagnose, monitor and treat cancer.
#LungCancer research has been central to building that understanding. #LCSM
nature.com/articles/s43018-0…
Filippo Gallina retweeted
Identifying biomarkers to optimize treatment selection is crucial in EGFRm NSCLC.
Now fully published in @CCR_AACR, our study investigated the impact of baseline EGFR amplification & how it influences the molecular landscape at resistance to osimertinib.
aacrjournals.org/clincancerr…
Filippo Gallina retweeted
I popoli del mare che non rispettano i fondamenti giuridici, etici e morali della civiltà - la legge di Zeus —, che conducono guerre e compiono genocidi ricorrendo a ogni mezzo persino al più abietto come l’inganno celato in un dono sacro, e che minacciano la civiltà siamo noi
1/
Filippo Gallina retweeted
🔥Improving neoadjuvant and perioperative therapy in NSCLC
🆙 @NatRevClinOncol
🎯ctDNA, radiomics & baseline biomarkers complement pCR to refine patient selection & adapt perioperative strategy
🎙 @YGaritaonaindia @HwakeleeMD @MartinReck2 @FordePatrick Dr. Tina Cascone @DoctorJSpicer @MARIANOPROVENCI
#LCSM @OncoAlert @Larvol
nature.com/articles/s41571-0…
